<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To study the origin and progress of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) with <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The data of twenty-five cases of hypomyeloplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> diagnosed by our department in the last ten years were analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>17 of the 25 cases were followed up for a long time </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: (1) The percentage of hypomyeloplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was 11.4% of the total 219 MDS patients </plain></SENT>
<SENT sid="4" pm="."><plain>The median age of the 25 cases was (44.8 +/- 14.7) years </plain></SENT>
<SENT sid="5" pm="."><plain>(2) FAB subtype: There were 11 cases of RA and 14 of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>(3) Hypomyeloplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> seems to be a developmental phase in the clinical course in some of the patients and not a special type of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Hyper- and hypo-myeloplasia could be transformed from one to another </plain></SENT>
<SENT sid="8" pm="."><plain>The transformation of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> could occur either in the same or and different FAB subtype </plain></SENT>
<SENT sid="9" pm="."><plain>(4) Seven of the seventeen cases transformed to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (41.2%), 6 cases were <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 1 was ALL </plain></SENT>
<SENT sid="10" pm="."><plain>3 of the 7 cases transformed to hypomyeloplastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and the remaining 4 transformed to hypermyeloplastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>(5) The median time from the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> to <z:hpo ids='HP_0001909'>leukemia</z:hpo> transformation, was 27 months in 7 cases with hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>(6) No relationship was found between therapeutic medicines and development of hypomyeloplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: It is suggested that hypomyeloplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is probably a developmental phase in the clinical course of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but not a special type </plain></SENT>
</text></document>